NL7107930A - Rubella vaccine - highly attenuated live form, free from side effects - Google Patents

Rubella vaccine - highly attenuated live form, free from side effects

Info

Publication number
NL7107930A
NL7107930A NL7107930A NL7107930A NL7107930A NL 7107930 A NL7107930 A NL 7107930A NL 7107930 A NL7107930 A NL 7107930A NL 7107930 A NL7107930 A NL 7107930A NL 7107930 A NL7107930 A NL 7107930A
Authority
NL
Netherlands
Prior art keywords
free
side effects
attenuated live
highly attenuated
vaccine
Prior art date
Application number
NL7107930A
Other versions
NL171123C (en
NL171123B (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to NLAANVRAGE7107930,A priority Critical patent/NL171123C/en
Publication of NL7107930A publication Critical patent/NL7107930A/en
Publication of NL171123B publication Critical patent/NL171123B/en
Application granted granted Critical
Publication of NL171123C publication Critical patent/NL171123C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/20—Rubella virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Title vaccine comprises live rubella virus Strain To-336 (ATCC VR 553) subjected to at least 10 passes and a physiologically acceptable carrier the strength of the vaccine being at least 102.0 InD50/ml after dilution in an inoculable form and is prepd by supplementary cultivation of a rubella virus having been subjected to 10 passes in a tissue culture contg live cells of the african monkey (Green Monkey), duck embryo or rabbit at 28-36 degrees C until sufficient attenuation has taken place.
NLAANVRAGE7107930,A 1971-06-09 1971-06-09 PROCESS FOR PREPARING A STRONGLY WEAKED RUBELLAVIRUS VACCINE. NL171123C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7107930,A NL171123C (en) 1971-06-09 1971-06-09 PROCESS FOR PREPARING A STRONGLY WEAKED RUBELLAVIRUS VACCINE.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7107930,A NL171123C (en) 1971-06-09 1971-06-09 PROCESS FOR PREPARING A STRONGLY WEAKED RUBELLAVIRUS VACCINE.

Publications (3)

Publication Number Publication Date
NL7107930A true NL7107930A (en) 1972-12-12
NL171123B NL171123B (en) 1982-09-16
NL171123C NL171123C (en) 1983-02-16

Family

ID=19813340

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7107930,A NL171123C (en) 1971-06-09 1971-06-09 PROCESS FOR PREPARING A STRONGLY WEAKED RUBELLAVIRUS VACCINE.

Country Status (1)

Country Link
NL (1) NL171123C (en)

Also Published As

Publication number Publication date
NL171123C (en) 1983-02-16
NL171123B (en) 1982-09-16

Similar Documents

Publication Publication Date Title
ES8502871A1 (en) Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain.
DK401981A (en) HERPES SIMPLEX TYPE 1 SUBSTANCE VACCINE AND PROCEDURES FOR PRODUCING THEREOF
Pennings et al. A test in vero cell monolayers for toxin production by strains of Pasteurella multocida isolated from pigs suspected of having atrophic rhinitis
ES501242A0 (en) A PROCEDURE FOR THE PREPARATION OF AN ANTIGENIC POLYSACCHARIDE.
ES467557A1 (en) Vaccines for immunizing egg-laying birds against Egg Drop disease, preparation of said vaccines, and method of use of said vaccines
JPS5527178A (en) Live influenza virus vaccine
DE3379937D1 (en) Production of antibodies
DE2962920D1 (en) Attenuated strain of feline infectious peritonitis virus, method for preparing it and vaccine comprising it
GB1492596A (en) Tetanus toxoid and process for its manufacture
FR2143572A1 (en) Rubella vaccine - highly attenuated live form, free from side effects
NL7107930A (en) Rubella vaccine - highly attenuated live form, free from side effects
BE768794A (en) Rubella vaccine - highly attenuated live form, free from side effects
PT67554A (en) New vaccine
Vincent et al. Duration of invasiveness of Entamoeba histolytica maintained in vitro
ES476703A1 (en) Heterovaccine against the trichomonas syndrome, and process for its preparation
GB928807A (en) Combined poliomyelitis-diphtheria-tetanus-pertussis antigen and methods for its manufacture
ES446637A1 (en) Acellular vaccines
GB1358321A (en) Method od tissue cell culture
SE8205247D0 (en) FISH VACCINES
Harrison A new subspecies of lesser long-winged bat Miniopterus minor Peters, 1867, from the Comoro Islands
ES8107300A1 (en) Herpes virus vaccine and its preparation.
GB1355259A (en) Attenuated rubella virus vaccine and production thereof
GB1135987A (en) Attenuated live rubella virus vaccine and method of production
SU520398A1 (en) The strain of bacteria N7402 serotype 49
Parker Some investigations with Beech bark disease Nectria in southern England 1

Legal Events

Date Code Title Description
V1 Lapsed because of non-payment of the annual fee